AtaiBeckley

AtaiBeckley Inc. is a clinical-stage biotechnology company developing treatments for mental health disorders, including therapies based on psychedelics, entactogens, and related compounds.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

AtaiBeckley Inc. is a clinical-stage biotechnology company developing treatments for mental health disorders, including therapies based on psychedelics, entactogens, and related compounds. It was formed in November 20251 through the combination of atai Life Sciences N.V. and Beckley Psytech Limited, and has been a wholly owned subsidiary of Eli Lilly and Company since September 2026.

See also

List of psychedelic pharmaceutical companies List of investigational hallucinogens and entactogens

Text derived from https://en.wikipedia.org/w/index.php?oldid=1375700300 under CC BY-SA 4.0; modifications have been made.

References

  1. ↩Wikipedia “AtaiBeckley” revision 1375700300 · retrieved 2026-10-20 date of formation (×1) · confidence 0.95 revision URL